Lipid metabolic reprogramming by hypoxia-inducible factor-1 in the hypoxic tumour microenvironment.

Jieun Seo, Jeong-Eun Yun, Sung Joon Kim, Yang-Sook Chun

Journal: Pflugers Archiv : European journal of physiology 2022;474(6):591-601

PMID: 35348849

Abstract

Cancer cells rewire metabolic processes to adapt to the nutrient- and oxygen-deprived tumour microenvironment, thereby promoting their proliferation and metastasis. Previous research has shown that modifying glucose metabolism, the Warburg effect, makes glycolytic cancer cells more invasive and aggressive. Lipid metabolism has also been receiving attention because lipids function as energy sources and signalling molecules. Because obesity is a risk factor for various cancer types, targeting lipid metabolism may be a promising cancer therapy. Here, we review the lipid metabolic reprogramming in cancer cells mediated by hypoxia-inducible factor-1 (HIF-1). HIF-1 is the master transcription factor for tumour growth and metastasis by transactivating genes related to proliferation, survival, angiogenesis, invasion, and metabolism. The glucose metabolic shift (the Warburg effect) is mediated by HIF-1. Recent research on HIF-1-related lipid metabolic reprogramming in cancer has confirmed that HIF-1 also modifies lipid accumulation, β-oxidation, and lipolysis in cancer, triggering its progression. Therefore, targeting lipid metabolic alterations by HIF-1 has therapeutic potential for cancer. We summarize the role of the lipid metabolic shift mediated by HIF-1 in cancer and its putative applications for cancer therapy.

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Address: Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, South Korea.; Department of Physiology, Seoul National University College of Medicine, Seoul, 03080, South Korea.; Faculty of Engineering, Yokohama National University, Yokohama, 240-8501, Japan.; Kanagawa Institute of Industrial Science and Technology, Kawasaki, 213-0012, Japan.; Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, 03080, South Korea.; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, South Korea. [email protected].; Department of Physiology, Seoul National University College of Medicine, Seoul, 03080, South Korea. [email protected].; Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, 03080, South Korea. [email protected].

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.